Lagging rivals, Teva eyes more studies of MS pill
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries may be fourth to market with a new multiple sclerosis pill in the US and Europe, trailing some competitors who are expected to have bigger-selling drugs.